[{"id":"f1b173cf-5e6a-4243-a2dc-cddb4fa79a72","acronym":"","url":"https://clinicaltrials.gov/study/NCT02370160","created_at":"2021-01-18T11:17:26.599Z","updated_at":"2024-07-02T16:36:51.390Z","phase":"Phase 1/2","brief_title":"HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma","source_id_and_acronym":"NCT02370160","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OXS-1550"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/21/2015","start_date":" 12/21/2015","primary_txt":" Primary completion: 04/08/2018","primary_completion_date":" 04/08/2018","study_txt":" Completion: 04/08/2018","study_completion_date":" 04/08/2018","last_update_posted":"2020-01-13"},{"id":"5e8b88b8-ff47-433a-a99e-7a4b183ba806","acronym":"","url":"https://clinicaltrials.gov/study/NCT00889408","created_at":"2021-01-18T03:24:18.974Z","updated_at":"2024-07-02T16:37:15.928Z","phase":"Phase 1","brief_title":"DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma","source_id_and_acronym":"NCT00889408","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OXS-1550"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/02/2013","start_date":" 12/02/2013","primary_txt":" Primary completion: 07/21/2014","primary_completion_date":" 07/21/2014","study_txt":" Completion: 07/21/2014","study_completion_date":" 07/21/2014","last_update_posted":"2017-12-02"}]